Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00029900 · ClinicalTrials.gov registry record · Phase 1
ADI-PEG in Patients With Metastatic Melanoma
A Phase 1 study, sponsored by FDA Office of Orphan Products Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT00029900 is a Phase 1 study that has completed, run by FDA Office of Orphan Products Development. The registered enrollment target is 15 participants.
The verdict
NCT00029900, a Phase 1 study, has completed, sponsored by FDA Office of Orphan Products Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
This is a study to determine the safety and toxicity of increasing doses of arginine deiminase combined to polyethylene glycol (ADI-PEG) in patients with nonresectable metastatic melanoma.
Interventions
- DRUG ADI PEG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2001-09 |
| Est. Completion | 2003-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00029900
The ClinicalTrials.gov registry entry for NCT00029900 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is FDA Office of Orphan Products Development, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ADI PEG is the first listed.
NCT00029900 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00029900 about?
NCT00029900 is a clinical study titled "ADI-PEG in Patients With Metastatic Melanoma". This is a study to determine the safety and toxicity of increasing doses of arginine deiminase combined to polyethylene glycol (ADI-PEG) in patients with nonresectable metastatic melanoma.
What is the current status of trial NCT00029900?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2001-09. Estimated completion is 2003-08.
What interventions are being tested in trial NCT00029900?
The interventions under investigation include: ADI PEG (DRUG).
Who is sponsoring clinical trial NCT00029900?
This trial is sponsored by FDA Office of Orphan Products Development, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.